Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.32 |
| ▸ | PPARG | P37231 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30720042 | 0.80 | TSHR (0.39) | TSHRTRPA1LTA4HCA4ALDH1A1 | |
| SCHEMBL10486820 | 0.76 | TSHR (0.37) | TSHRTRPA1LTA4HCA4ALDH1A1 | |
| SCHEMBL3961288 | 0.76 | TSHR (0.37) | TSHRTRPA1LTA4HCA4ALDH1A1 | |
| SCHEMBL4306370 | 0.76 | KDM4E (0.39) | TSHRTRPA1LTA4HCA4ALDH1A1 | |
| SCHEMBL11388127 | 0.76 | TRPA1 (0.46) | TSHRTRPA1LTA4HCA4ALDH1A1 | |
| SCHEMBL6425390 | 0.75 | TSHR (0.45) | TSHRTRPA1LTA4HALDH1A1RECQL | |
| SCHEMBL4516165 | 0.73 | CA4 (0.41) | TSHRTRPA1LTA4HCA4ALDH1A1 | |
| SCHEMBL11683951 | 0.72 | TSHR (0.36) | TSHRLTA4HCA4ALDH1A1SLC6A4 | |
| SCHEMBL1941689 | 0.72 | CYP1A2 (0.42) | TSHRMTNR1AMTNR1BPPARGPPARA | |
| SCHEMBL27960911 | 0.72 | ALDH1A1 (0.44) | TSHRALDH1A1KDM4ECHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1762567-B1 | Pyrazole derivatives for treating HIV | PFIZER LTD (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20120029192-A1 | Pyrazole Derivatives | PFIZER INC | 2012-02-02 | — | — | US | disclosed |
| US-8063044-B2 | Pyrazole derivatives | PFIZER INC. (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | PFIZER INC | 2009-08-27 | — | — | US | disclosed |
| US-7435728-B2 | Pyrazole derivatives | PFIZER INC (US) | 2008-10-14 | — | — | US | disclosed |
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | disclosed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | disclosed |
| US-7109228-B2 | Pyrazole derivatives | AGOURON PHARMACEUTICALS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20060020012-A1 | Pyrazole derivatives | PFIZER INC | 2006-01-26 | — | — | US | disclosed |
| US-20040133002-A1 | Pyrazole derivatives | PFIZER, INC. | 2004-07-08 | — | — | US | disclosed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | disclosed |
| EP-0170906-B1 | PLANT-PROTECTING AGENTS BASED ON OXIME ESTERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-03-07 | — | — | EP | disclosed |
| US-3944560-A | BRONCHODILATOR | MERCK & CO., INC. (US) | 1976-03-16 | — | — | US | disclosed |
| US-3907861-A | Cyanophenoxyacetonitriles | SCHERING AG | 1975-09-23 | — | — | US | disclosed |
| US-3907861-A | Cyanophenoxyacetonitriles | SCHERING AG | 1975-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215712-A1 | PYRAZOLE DERIVATIVES | RRM2B, REV1, RRM2 | TSHR 2158/4885TRPA1 4019/4885LTA4H 1119/4885 |
| US-20040133002-A1 | Pyrazole derivatives | REV1, RRS1, CYP2F1 | TSHR 3528/4885TRPA1 4695/4885LTA4H 1621/4885 |
| US-20060020012-A1 | Pyrazole derivatives | PDCD11, RTF1, REV1 | TSHR 2613/4885TRPA1 4187/4885LTA4H 1376/4885 |
| US-20120029192-A1 | Pyrazole Derivatives | POLRMT, PDCD11, DPYD | TSHR 3856/4885TRPA1 4438/4885LTA4H 1802/4885 |
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | TSHR 4085/4885TRPA1 4300/4885LTA4H 1945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.